• Due to the discontinuation of the activities aimed at establishing its own SOEC mass manufacturing capacities and the resulting one-off earnings effect, thyssenkrupp nucera expects EBIT in a range between EUR -155 million and EUR -135 million for fiscal year 2025/26 (2024/25: EUR -56 million). Previously, thyssenkrupp nucera had expected EBIT between EUR -125 million and EUR -90 million. Based on ongoing business performance, sales expectations for the gH2 segment are adjusted to EUR 100 million to EUR 130 million (2024/25: EUR 459 million). Previously, thyssenkrupp nucera had expected gH2 sales of EUR 120 million to EUR 170 million.

• Guidance for the Chlor-Alkali (CA) segment remains unchanged. The sales range of EUR 320 million to EUR 400 million is confirmed (2024/25: EUR 387 million). EBIT is still expected to amount to EUR 45 million to EUR 65 million (2024/25: EUR 58 million).
• At Group level, the sales guidance range is refined on the basis of ongoing business performance at EUR 450 million to EUR 500 million (2024/25: EUR 845 million). Previously, thyssenkrupp nucera had expected Group sales between EUR 450 million and EUR 550 million. Taking into account the SOEC realignment, the EBIT range is adjusted to EUR -105 million to EUR -75 million (2024/25: EUR 2 million). Previously, expectations for Group EBIT ranged between EUR -80 million and EUR -30 million.
• thyssenkrupp nucera is also refining order intake guidance for the Group within the previously communicated range and now expects order intake between EUR 550 million and EUR 670 million for fiscal year 2025/26 (2024/25: EUR 348 million). Previously, the guidance range had been EUR 550 million to EUR 850 million.

2380956  11-Aug-2026 CET/CEST